Radiation before surgery for recurrent adrenal cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether giving radiation before surgery helps people with adrenal cancer that has come back after previous treatment. It aims to see if this approach can improve outcomes for patients who can have surgery at the NIH.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your adrenal cancer has come back and can be removed with surgery.
- You are well enough to have both radiation and surgery.
- You agree to have a tumor biopsy before starting treatment.
- You have not had radiation to the belly area before.
- You are not pregnant and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
This study compares the use of radiation therapy after surgery versus simply monitoring for patients with high-risk adrenocortical carcinoma (ACC) that hasn't spread. The goal is to see if radiation helps prevent the cancer from coming back.
This study looks at whether giving mitotane after surgery (and possibly adding cisplatin/etoposide chemotherapy) helps prevent adrenal cancer from coming back. It is for people with stage I–III adrenal cortical cancer who have a high risk of relapse after their tumor was removed.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
This trial studies a targeted, high-intensity radiation approach given after prostate removal surgery when prostate cancer seems to be coming back locally. It may help control the disease in the pelvis while avoiding treatment that could cause more side effects.
This trial tests whether combining camrelizumab (an immune treatment) with apatinib (a targeted drug) can shrink recurrent or metastatic adrenal cancer after standard treatment didn’t work. It may help some people control tumor growth when other treatments have already been tried.
Hear when a new Adrenocortical Carcinoma (ACC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.